These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38310920)

  • 1. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.
    Koren MJ; Descamps O; Hata Y; Hengeveld EM; Hovingh GK; Ikonomidis I; Radu Juul Jensen MD; Langbakke IH; Martens FMAC; Søndergaard AL; Witkowski A; Koenig W
    Lancet Diabetes Endocrinol; 2024 Mar; 12(3):174-183. PubMed ID: 38310920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
    Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
    Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
    Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
    Giugliano RP; Pedersen TR; Park JG; De Ferrari GM; Gaciong ZA; Ceska R; Toth K; Gouni-Berthold I; Lopez-Miranda J; Schiele F; Mach F; Ott BR; Kanevsky E; Pineda AL; Somaratne R; Wasserman SM; Keech AC; Sever PS; Sabatine MS;
    Lancet; 2017 Oct; 390(10106):1962-1971. PubMed ID: 28859947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
    N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
    JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
    Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
    Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT.
    Santos RD; Ruzza A; Hovingh GK; Stefanutti C; Mach F; Descamps OS; Bergeron J; Wang B; Bartuli A; Buonuomo PS; Greber-Platzer S; Luirink I; Bhatia AK; Raal FJ; Kastelein JJP; Wiegman A; Gaudet D
    Lancet Diabetes Endocrinol; 2022 Oct; 10(10):732-740. PubMed ID: 36075246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
    N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
    Rosenson RS; Daviglus ML; Handelsman Y; Pozzilli P; Bays H; Monsalvo ML; Elliott-Davey M; Somaratne R; Reaven P
    Diabetologia; 2019 Jun; 62(6):948-958. PubMed ID: 30953107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
    Fitzgerald K; Frank-Kamenetsky M; Shulga-Morskaya S; Liebow A; Bettencourt BR; Sutherland JE; Hutabarat RM; Clausen VA; Karsten V; Cehelsky J; Nochur SV; Kotelianski V; Horton J; Mant T; Chiesa J; Ritter J; Munisamy M; Vaishnaw AK; Gollob JA; Simon A
    Lancet; 2014 Jan; 383(9911):60-68. PubMed ID: 24094767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.